Oscar Ratnoff

Q: What Schools Are Affiliated With Oscar Ratnoff

Oscar Ratnoff is affiliated with the following schools: Case Western Reserve University, Columbia University, Harvard University

Oscar Ratnoff's AcademicInfluence.com Rankings

Oscar Ratnoff

Medical

#388

World Rank

#545

Historical Rank

#162

USA Rank

Hematology

World Rank

Historical Rank

USA Rank

medical Degrees

Oscar Ratnoff

Philosophy

#2263

World Rank

#3910

Historical Rank

#831

USA Rank

Logic

#507

World Rank

#932

Historical Rank

#202

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Oscar Ratnoff Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Oscar Davis Ratnoff was an American physician who conducted research on the process of coagulation and blood-related disorders. Ratnoff discovered the substance later known as Factor XII and was one of the primary contributors to the delineation of the exact sequence that makes up the clotting cascade. He also made notable research contributions to the understanding of the complement system and to the detection and treatment of hemophilia.

(See a Problem?)

Oscar Ratnoff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Waterfall Sequence for Intrinsic Blood Clotting (1964) (1085)
A new method for the determination of fibrinogen in small samples of plasma. (1951) (1016)
Immunologic differentiation of classic hemophilia (factor 8 deficiency) and von Willebrand's dissase, with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. (1971) (586)
A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. (1955) (438)
Impaired cell-mediated immunity in patients with classic hemophilia. (1983) (324)
CIRCULATING ANTICOAGULANTS: A STUDY OF 40 CASES AND A REVIEW OF THE LITERATURE (1961) (298)
THE NATURAL HISTORY OF LAENNEC'S CIRRHOSIS OF THE LIVER AN ANALYSIS OF 386 CASES (1942) (291)
THE INHIBITION OF PLASMIN, PLASMA KALLIKREIN, PLASMA PERMEABILITY FACTOR, AND THE C'1r SUBCOMPONENT OF THE FIRST COMPONENT OF COMPLEMENT BY SERUM C'1 ESTERASE INHIBITOR (1969) (290)
Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. (1994) (289)
Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. (1954) (240)
Studies on the action of Hageman factor: evidence that activated Hageman factor in turn activates plasma thromboplastin antecedent. (1961) (218)
Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. (1970) (211)
THE CONVERSION OF C'1S TO C'1 ESTERASE BY PLASMIN AND TRYPSIN (1967) (205)
Thrombosis or Myocardial Infarction in Congenital Clotting Factor Abnormalities and Chronic Thrombocytopenias: A Report of 21 Patients and a Review of 50 Previously Reported Cases (1983) (204)
Fitzgerald Trait: Deficiency of a Hitherto Unrecognized Agent, Fitzgerald Factor, Participating in Surface-Mediated Reactions of Clotting, Fibrinolysis, Generation of Kinins, and the Property of Diluted Plasma Enhancing Vascular Permeability (PF/Dil). (1975) (196)
Role of Hageman factor in the initiation of clotting by glass; evidence that glass frees Hageman factor from inhibition. (1958) (187)
Detection of carriers of classic hemophilia using an immunologic assay for antihemophilic factor (factor 8(). (1971) (169)
SOME PROPERTIES OF AN ESTERASE DERIVED FROM PREPARATIONS OF THE FIRST COMPONENT OF COMPLEMENT (1957) (160)
ACTIVATION OF HAGEMAN FACTOR BY SOLUTIONS OF ELLAGIC ACID. (1964) (158)
Studies on a complex mechanism for the activation of plasminogen by kaolin and by chloroform: the participation of Hageman factor and additional cofactors. (1969) (147)
Studies on a procoagulant fraction of southern copperhead snake venom: the preferential release of fibrinopeptide B. (1970) (135)
Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. (1969) (133)
Coincident classic hemophilia and "idiopathic" thrombocytopenic purpura in patients under treatment with concentrates of antihemophilic factor (factor VIII). (1983) (131)
Activation of Hageman Factor by L-Homocystine (1968) (128)
Dietary treatment of cirrhosis of the liver. Results in one hundred and twenty-four patients observed during a ten year period. (1948) (127)
The purification of activated Hageman factor (activated factor XII). (1962) (125)
Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. (1969) (123)
Factor XI (plasma thromboplastin antecedent) deficiency in Ashkenazi Jews is a bleeding disorder that can result from three types of point mutations. (1989) (121)
Changes in antihemophilic factor (AHF, factor 8) procoagulant activity and AHF-like antigen in normal pregnancy, and following exercise and pneumoencephalography. (1972) (120)
The Activation of Christmas Factor (Factor IX) by Activated Plasma Thromboplastin Antecedent (Activated Factor XI) (1962) (115)
Defective Activation of Clotting, Fibrinolytic, and Permeability‐Enhancing Systems in Human Fletcher Trait Plasma (1974) (106)
Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives. (1980) (106)
Role of Hageman Factor in the Activation of Vasodilator Activity in Human Plasma (1961) (104)
Observations on a Pro-esterase Associated with Partially Purified First Component of Human Complement (C'1).∗ (1956) (104)
THE ENZYMATIC NATURE OF C'1r CONVERSION OF C'1s TO C'1 ESTERASE AND DIGESTION OF AMINO ACID ESTERS BY C'1r (1968) (101)
Disorders of Hemostasis (1991) (98)
THE INACTIVATION OF COMPLEMENT AND ITS COMPONENTS BY PLASMIN (1953) (94)
Adsorption of Hageman factor (factor XII) and other human plasma proteins to biomedical polymers. (1990) (92)
Morphologic characteristics of adsorbed human plasma proteins on vascular grafts and biomaterials. (1990) (91)
Immunologic studies in von Willebrand's disease. Evidence that the antihemophilic factor (AHF) produced after transfusions lacks an antigen associated with normal AHF and the inactive material produced by patients with classic hemophilia. (1972) (90)
STUDIES ON THE ACTIVATION OF A PROESTERASE ASSOCIATED WITH PARTIALLY PURIFIED FIRST COMPONENT OF HUMAN COMPLEMENT (1958) (90)
STUDIES ON THE PATHOGENESIS OF THROMBOSIS: AN EXPERIMENTAL "HYPERCOAGULABLE" STATE INDUCED BY THE INTRAVENOUS INJECTION OF ELLAGIC ACID. (1964) (86)
The secondary structure of human Hageman factor (factor XII) and its alteration by activating agents. (1974) (85)
COMPLEMENT AS A MEDIATOR OF INFLAMMATION. ENHANCEMENT OF VASCULAR PERMEABILITY BY PURIFIED HUMAN C'1 ESTERASE. (1963) (82)
Observations on the clotting defect in amniotic-fluid embolism. (1952) (80)
PSYCHOGENIC PURPURA: A RE-EVALUATION OF THE SYNDROME OF AUTOERYTHROCYTE SENSITIZATION (1968) (79)
An inherited qualitative abnormality in plasma fibrinogen: fibrinogen Cleveland. (1968) (76)
Epsilon aminocaproic acid--a dangerous weapon. (1969) (75)
PATHOGENESIS OF INFLAMMATION. II. IN VIVO OBSERVATIONS OF THE INFLAMMATORY EFFECTS OF ACTIVATED HAGEMAN FACTOR AND BRADYKININ. (1965) (73)
Radioimmunoassay of human Hageman factor (factor XII). (1976) (72)
The changing prognosis of classic hemophilia (factor VIII "deficiency"). (1991) (72)
Acceleration of fibrin polymerization by calcium ions. (1972) (72)
Studies on the mechanism of inactivation of human complement by plasmin and by antigen-antibody aggregates. I. The requirement for a factor resembling C'1 and the role of Ca++. (1954) (71)
Studies on the purification of antihemophilic factor (factor 8. I. Precipitation of antihemophilic factor by concanavalin A. (1969) (70)
Psychogenic purpura (autoerythrocyte sensitization): an unsolved dilemma. (1989) (67)
Generation of kinin-like agents by chondroitin sulfate, heparin, chitin sulfate, and human articular cartilage: possible pathophysiologic implications. (1970) (66)
The blood-clotting mechanism during normal parturition. (1954) (66)
THE REACTION BETWEEN ACTIVATED PLASMA THROMBOPLASTIN ANTECEDENT AND DIISOPROPYLPHOSPHOFLUORIDATE. (1964) (65)
Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). (1992) (60)
Elution of an Esterase from Antigen-Antibody Aggregates Treated with Human Complement.∗ (1956) (60)
Studies on the purification of antihemophilic factor (factor VIII). II. Separation of partially purified antihemophilic factor by gel filtration of plasma. (1969) (59)
Primary pulmonary hypertension in patients with classic hemophilia. (1988) (59)
Bovine plasma thromboplastin antecedent (Factor XI) deficiency. (1969) (57)
Studies on a proteolytic enzyme in human plasma. VII. A fatal hemorrhagic state associated with excessive plasma proteolytic activity in a patient undergoing surgery for carcinoma of the head of the pancreas. (1952) (57)
Hageman Factor: Alterations in Physical Properties during Activation (1965) (57)
Failure to detect variant (CRM+) plasma thromboplastin antecedent (factor XI) molecules in hereditary plasma thromboplastin antecedent deficiency: a study of 125 patients of several ethnic backgrounds. (1985) (56)
Hemorrhagic states during pregnancy. (1955) (56)
Detection of the carrier state for classic hemophilia. (1973) (55)
Studies on a family with combined functional deficiencies of vitamin K-dependent coagulation factors. (1982) (55)
Surface-mediated reactions. (1979) (53)
THE CLOT-PROMOTING EFFECT OF SOAPS OF LONG-CHAIN SATURATED FATTY ACIDS. (1963) (52)
Multiple coagulative defects in a patient with the Waterhouse-Friderichsen syndrome. (1962) (52)
Antihemophilic factor [factor VIII] preparations inhibit lymphocyte proliferation and production of interleukin-2. (1986) (51)
Partial purification of plasma thromboplastin antecedent (factor XI) and its activation by trypsin. (1973) (49)
The accelerating effect of calcium and other cations on the conversion of fibrinogen to fibrin. (1954) (49)
Studies on a proteolytic enzyme in human plasma. IX. Fibrinogen and fibrin as substrates for the proteolytic enzyme of plasma. (1953) (48)
Clues to the pathogenesis of bleeding in von Willebrand's disease. (1973) (48)
Total knee arthroplasty in classic hemophilia. (1981) (48)
PULMONARY EMBOLISM AND UNEXPECTED DEATH IN SUPPOSEDLY NORMAL PERSONS. (1964) (47)
Acquisition of antibody to lymphadenopathy-associated virus in patients with classic hemophilia (factor VIII deficiency). (1985) (47)
COAGULATION COMPONENTS IN NORMAL AND ABNORMAL PREGNANCIES * (1959) (45)
Amidolytic properties of single-chain activated Hageman factor. (1979) (45)
INCREASED VASCULAR PERMEABILITY INDUCED BY HUMAN PLASMIN (1965) (45)
Purpura as a psychosomatic entity. A psychiatric study of autoerythrocyte sensitization. (1962) (44)
An accelerating property of plasma for the coagulation of fibrinogen by thrombin. (1954) (44)
Mitogenic effects of coagulation factor XII and factor XIIa on HepG2 cells. (1991) (42)
Production and release of plasminogen by isolated perfused rat liver. (1980) (42)
Studies on the nature of antihemophilic factor (factor VIII). Further evidence relating the AHF-like antigens in normal and hemophilic plasmas. (1973) (41)
The genetics of hereditary disorders of blood coagulation. (1973) (41)
STUDIES ON THE SITE OF ACTION OF A CIRCULATING ANTICOAGULANT IN DISSEMINATED LUPUS ERYTHEMATOSUS. EVIDENCE THAT THIS ANTICOAGULANT INHIBITS THE REACTION BETWEEN ACTIVATED STUART FACTOR (FACTOR X) AND PROACCELERIN (FACTOR V). (1963) (41)
The laboratory diagnosis of the carrier state for classic hemophilia. (1977) (39)
Studies on plasma thromboplastin antecedent (factor XI), PTA deficiency and inhibition of PTA by plasma: pharmacologic inhibitors and specific antiserum. (1972) (39)
Activation of Hageman factor (factor XII) by sulfatides and other agents in the absence of plasma proteases. (1983) (39)
Observations on hemophilia, parahemophilia, and coexistent hemophilia and parahemophilia; alterations in the platelets and the thromboplastin generation test. (1958) (38)
STUDIES ON A PROTEOLYTIC ENZYME IN HUMAN PLASMA (1952) (38)
Studies on the response of patients with classic hemophilia to transfusion with concentrates of antihemophilic factor. A difference in the half-life of antihemophilic factor as measured by procoagulant and immunologic techniques. (1972) (38)
Observations on the characteristics of an unusual circulating anticoagulant. (1951) (37)
THE INFLUENCE OF CALCIUM IONS ON THE INACTIVATION OF HUMAN COMPLEMENT AND ITS COMPONENTS BY PLASMIN (1953) (37)
Reduced titers of Hageman factor (factor XII) in Orientals. (1981) (36)
Hemostatic mechanisms in liver disease. (1963) (35)
The Role of Proaccelerin in Human Blood Coagulation. Evidence that Proaccelerin Is Converted to a Prothrombin-converting Principle by Activated Stuart Factor: With Notes on the Anticoagulant Action of Soybean Trypsin Inhibitor, Protamine Sulfate, and Hexadimethrine Bromide. (1965) (35)
The biology and pathology of the initial stages of blood coagulation. (1966) (35)
Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): a potential link between the intrinsic and extrinsic blood-clotting systems. (1975) (34)
Fibrinolysis, thrombocytopenia, and coagulation abnormalities complicating high-dose interleukin-2 immunotherapy. (1991) (34)
Activation of Hageman factor (factor XII) by bismuth subgallate, a hemostatic agent. (1988) (34)
STUDIES ON A PROTEOLYTIC ENZYME IN HUMAN PLASMA (1948) (34)
Evidence that functional subunits of antihemophilic factor (Factor VIII) are linked by noncovalent bonds. (1976) (34)
Familial Sneddon's syndrome (1994) (33)
Experiments on the Nature of the Prothrombin‐Converting Principle: Alteration of Proaccelerin Thrombin (1967) (33)
The anticoagulant malingerer. Psychiatric studies of three patients. (1970) (32)
Hemorrhagic Diseases and Thrombosis (1966) (32)
Postnecrotic cirrhosis of the liver; a study of forty-five cases. (1955) (32)
Immunologic evidence that the properties of human antihemophilic factor (factor VIII) are attributes of a single molecular species. (1976) (32)
Hageman trait: an asymptomatic disorder of blood coagulation. (1955) (32)
Interactions among Hageman factor, plasma prekallikrein, high molecular weight kininogen, and plasma thromboplastin antecedent. (1979) (31)
The Evolution of Hemostatic Mechanisms (2015) (31)
Studies of fibrinogen and other hemostatic factors in women with intrauterine death and delayed delivery. (1955) (31)
The psychogenic purpuras: a review of autoerythrocyte sensitization, autosensitization to DNA, "hysterical" and factitial bleeding, and the religious stigmata. (1980) (31)
The influence of estrogen and prolactin on Hageman factor (factor XII) titer in ovariectomized and hypophysectomized rats. (1985) (31)
Observations on the hereditary nature of Hageman trait. (1956) (30)
Inhibition of the activation of Hageman factor (factor XII) by beta 2-glycoprotein I. (1988) (29)
A laboratory study of the carrier state in classic hemophilia. (1956) (29)
Heterogeneity of human circulating anticoagulants against antihemophilic factor (factor VIII). (1975) (28)
Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A. (1974) (28)
The remarkable Dr. Abildgaard and countershock. The bicentennial of his electrical experiments on animals. (1975) (28)
The multiplicity of plasmin inhibitors in human serum, demonstrated by the effect of primary amino compounds. (1954) (27)
Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol) (1992) (27)
A Quarter Century with Mr. Hageman (1980) (27)
The role of augmented Hageman factor (factor XII) titers in the cold-promoted activation of factor VII and spontaneous shortening of the prothrombin time in women using oral contraceptives. (1982) (27)
Conversion reactions in autoerythrocyte sensitization; their relationship to the production of ecchymoses. (1969) (26)
Studies on the product of the reaction between activated Hageman factor (factor XII) and plasma thromboplastin antecedent (factor XI). (1972) (26)
Wasp sting anaphylaxis. (1983) (25)
Studies on the initiation of blood coagulation. II. An anticoagulant inhibiting the activation of a plasma thromboplastic factor. (1950) (25)
STUDIES ON A PROTEOLYTIC ENZYME IN HUMAN PLASMA (1948) (25)
THE LOCALIZED ACTION ON THE SPINAL CORD OF INTRAMUSCULARLY INJECTED TETANUS TOXIN (1942) (24)
TREATMENT OF HÆMOPHILIA (FACTOR-VIII DEFICIENCY) WITH HUMAN ANTIHÆMOPHILIC FACTOR PREPARED BY THE CRYOPRECIPITATE PROCESS (1967) (24)
COMPLEMENT AS A MEDIATOR OF INFLAMMATION (1963) (24)
Airway obstruction in hemophilia (factor VIII deficiency): A 28‐year institutional review (1994) (24)
Detection by Fluorescence of Structural Changes Accompanying the Activation of Hageman Factor (Factor XII) (1977) (24)
Heparin cofactor II activity in plasma during pregnancy and oral contraceptive use. (1989) (24)
A hemorrhagic state during pregnancy with the presence of maternal Rh antibodies, death of the fetus and hypofibrinogenemia. (1952) (23)
Augmented Hageman factor and prolactin titers, enhanced cold activation of factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction. (1987) (23)
Inheritance of fibrin-stabilising-factor deficiency. (1968) (23)
Fletcher Factor Activity in Plasmas of Various Species 1 (1974) (23)
The role of prekallikrein and high-molecular-weight kininogen in the contact activation of Hageman factor (factor XII) by sulfatides and other agents. (1983) (23)
Inherited incomplete deficiency of the fourth component of complement (C4) determined by a gene not linked to human histocompatibility leukocyte antigens. (1984) (22)
Studies in Autoerythrocyte Sensitization: The Induction of Purpuric Lesions by Hypnotic Suggestion (1967) (22)
The normal coagulation mechanism. (1972) (22)
The prevalence of plasma thromboplastin antecedent (PTA, factor XI) deficiency. (1974) (22)
The Interrelationship of Clotting and Immunologic Mechanisms (1971) (21)
Inhibition of the activation of Hageman factor (factor XII) by β2-glycoprotein I (1988) (21)
Studies on afibrinogenemia. II. The defibrinating effect on dog blood of intravenous injection of thromboplastic material. (1951) (20)
Studies on some coagulation factors (Hageman factor, plasma prekallikrein, and high molecular weight kininogen) in the normal newborn. (1980) (20)
Hageman trait (factor XII deficiency): a probably second genotype inherited as an autosomal dominant characteristic. (1972) (20)
Immunologic demonstration of a deficiency of Hageman factor-like material in Hageman trait. (1967) (20)
A study of thrombocytopenia. New histologic criteria for the differentiation of idiopathic thrombocytopenia and thrombocytopenia associated with disseminated lupus erythematosus. (1967) (19)
Inhibition of the activation of Hageman factor (factor XII) by extracts of Schistosoma mansoni. (1992) (19)
Inhibition of the activation of Hageman factor (factor XII) by platelet factor 4. (1988) (19)
Plasma inhibition of activated plasma thromboplastin antecedent (factor XIa) in pregnancy. (1972) (19)
The Assay of a Plasma Component Necessary for the Generation of a Plasminogen Activator in the Presence of Hageman Factor (Hageman Factor Co‐factor) (1971) (19)
Detection of the carrier state for classic hemophilia using an enzyme-linked immunosorbent assay (ELISA). (1982) (19)
The relationship of the properties of antihemophilic factor (factor VIII) that support ristocetin-induced platelet agglutination (factor VIIIR:RC) and platelet retention by glass beads as demonstrated by a monoclonal antibody. (1983) (19)
Inhibition of the activation of hageman factor (factor XII) by eosinophils and eosinophilic constituents (1993) (18)
Antihemophilic factor (factor VIII). (1978) (18)
Pulmonary embolism and unexpected death in supposedly normal persons. A second look. (1970) (18)
Elevated antihemophilic factor (AHF, factor VIII) procoagulant activity and AHF-like antigen in alcoholic cirrhosis of the liver. (1974) (17)
Studies on the inhibition of ellagic acid-activated Hageman factor (factor XII) and Hageman factor fragments. (1981) (17)
Studies on the Blood Clotting and Fibrinolytic System in the Plasma from a Sei (Baleen) Whale 1 (1976) (17)
Partial purification and some properties of a plasma inhibitor of activated plasma thromboplastin antecedent (factor XI). (1972) (17)
Defective Esterase and Kinin‐Forming Activity in Human Fletcher Trait Plasma: A Fraction Rich in Kallikreinlike Activity (1974) (16)
Inhibition of the adsorption of Hagemen factor (Factor XII) to glass by normal human plasma. (1974) (16)
Immunologic evidence that the antihemophilic factor (factor VIII)-like material in hemophilic plasma possesses a nonfunctional low molecular weight subcomponent. (1977) (16)
Lymphadenopathy in a hemophiliac patient and his sexual partner. (1984) (15)
Studies on the conversion of prothrombin to thrombin: with notes on the cation requirement for this reaction. (1967) (15)
Influence of augmented Hageman factor (Factor XII) titers on the cryoactivation of plasma prorenin in women using oral contraceptive agents. (1983) (15)
Hemostatic Defects and Increased Red Cell Destruction in Preeclampsia and Eclampsia (1954) (15)
Purification of Hageman factor (factor XII) on columns of popcorn-agarose. (1986) (14)
Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction. (1987) (14)
The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid. (1982) (14)
Physiologic and pathologic effects of increased fibrinolytic activity in man. With notes on the effects of exercise and certain inhibitors on fibrinolysis. (1960) (14)
Inhibition of normal clotting and Fletcher factor activity by rabbit anti-kallikrein antiserum (1974) (13)
STUDIES ON A PROTEOLYTIC ENZYME IN HUMAN PLASMA (1948) (13)
Evidence that Fitzgerald factor counteracts inhibition by kaolin or ellagic acid of the amidolytic properties of a plasma kallikrein. (1976) (13)
Studies on the clot-promoting effect of skin. (1969) (13)
Inhibition of Ellagic Acid-Activated Hageman Factor (Factor XII) and Hageman Factor Fragments by Popcorn Inhibitor 1 (1981) (13)
Inhibition of the activation of Hageman factor (factor XII) and of platelet aggregation by extracts of Brugia malayi microfilariae. (1991) (13)
Studies on a proteolytic enzyme in human plasma; the relationship between the proteolytic activity of plasma and blood coagulation. (1950) (13)
FIBRIN CROSS‐LINKING and HEREDITY * (1972) (12)
Cabbage seed protease inhibitor: a slow, tight-binding inhibitor of trypsin with activity toward thrombin, activated Stuart factor (factor Xa), activated Hageman factor (factor XIIa), and plasmin. (1990) (12)
Inhibition of the activation of Hageman factor (factor XII) by soluble human placental collagens types III, IV, and V. (1991) (12)
Techniques for demonstration of the specificity of circulating anticoagulants against antihemophilic factor (factor VIII), with studies of two cases possibly related to diphenylhydantoin therapy. (1977) (12)
COAGULATION FACTORS AND THE ROLE OF SURFACE IN THEIR ACTIVATION * (1977) (12)
Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy. (1992) (11)
Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates. (1991) (11)
The activation of proaccelerin by bovine thrombokinase (with notes on the antithrombic activity of phenylmethyl sulfonylfluoride). (1966) (11)
Factor VIII concentrates. (1986) (10)
Brief Reviews: Some Recent Advances in the Study of Hemostasis (1974) (10)
Letter: Bleeding in von Willebrand's disease. (1974) (10)
Treatment of haemophilia (factor-8 deficiency) with human antihaemophilic factor prepared by the cryoprecipitate process. (1967) (10)
A monoclonal antibody that inhibits activation of human Hageman factor (factor XII). (1985) (10)
Studies on a circulating anticoagulant inhibiting factor XI in a patient with congenital deficiency and carcinoma of the prostate (1986) (10)
On the epidemiology of hemophilia and Christmas disease. (1957) (10)
Inhibition of Hageman factor (factor XII) by popcorn inhibitor. (1985) (10)
Enhancement of Vascular Permeability by Mixtures of C'l Esterase and Normal Serum.∗ (1964) (10)
Heckathorn's disease: variable functional dificiency of antihemophilic factor (factor VIII). (1975) (9)
Platelets and Surface‐Mediated Clotting Activity (1979) (9)
The Action of Russell's Viper Venom on Factor V and the Prothrombin‐Converting Principle (1969) (9)
Inhibition of the activation of Hageman factor (factor XII) by complement subcomponent C1q. (1987) (9)
The inhibitory properties of plasma against activated plasma thromboplastin antecedent (factor XIa) in hereditary angioneurotic edema. (1972) (9)
The role of surface and of calcium in the coagulation of a globulin fraction of platelet-deficient plasma. (1951) (9)
Studies on afibrinogenemia. I. Afibrinogenemia in a patient with septic abortion, acute yellow atrophy of the liver and bacteremia due to E. coli. (1951) (9)
Criteria for the differentiation of dysfibrinogenemic states. (1976) (9)
The coronary circulation. (1946) (8)
Fibronectin levels in congenital thrombocytopenia: Schulman's syndrome. (1982) (8)
Hemostatic emergencies in malignancy. (1989) (8)
Effect of Some Analogues of Bradykinin Upon Vascular Permeability.∗ (1967) (8)
Chapter 16 – The Proteins of Blood Coagulation (1965) (8)
Current clotting concepts in urology. (1976) (8)
Normal plasma arginine esterase and the Hageman factor (factor XII) -prekallikrein-kininogen system in cystic fibrosis. (1977) (8)
THE ENHANCEMENT OF CHLOROFORM-INDUCED PLASMA PROTEOLYTIC ACTIVITY BY EPSILON AMINOCAPROIC ACID (1962) (8)
Impaired cell-mediated immunity in hemophilia. II. Persistence of subclinical immunodeficiency and enhancement of natural killer activity by lymphokines. (1985) (8)
Inhibitory action of amyloid precursor protein against human Hageman factor (factor XII). (1995) (8)
Genetic disorders of blood coagulation. (1967) (7)
Notes on clotting in a Burmese python (Python molurus bivittatus). (1990) (7)
Comparative Studies of Hageman Factor (Factor XII) in Mammalian Plasmas by Immunological Techniques 1 (1979) (6)
The relative amidolytic activity of Hageman factor (factor XII) and its fragments. The effect of high-molecular-weight kininogen and kaolin. (1980) (6)
The detection of carriers of classic hemophilia. H. P. Smith Memorial Lecture. (1976) (6)
Relation of Acetyl Choline to Anaphylactic Shock in the Rabbit.∗ (1939) (6)
Treatment of hemorrhagic disorders (1968) (6)
Inhibition of Hageman Factor, Plasma Thromboplastin Antecedent, Thrombin and Other Clotting Factors by Phenylglyoxal Hydrate 1 (1975) (6)
THE ENZYMATIC NATURE OF C'1r (1968) (6)
Stigmata: where mind and body meet. A study of autoerythrocyte sensitization. (1969) (6)
Confirmation of mendelian properties of heterodimeric fibrinogen molecules in a heterozygotic dysfibrinogenemia, "fibrinogen Amarillo," using gprphoresis to differentiate semifibrin molecules from fibrinogen and fibrin. (2001) (6)
Prothrombin complex preparations: a cautionary note. (1974) (5)
Detection of Carriers of Classic Haemophilia (1973) (5)
Autoerythrocyte sensitization: psychiatric patterns in patients with a peculiar protracted purpura. (1961) (5)
Inhibition of the activation of Hageman factor (factor XII) by peripheral blood cells. (1987) (5)
An inhibitor of antihemophilic factor (factor VIII) in an 18-month-old nonhemophilic child. (1993) (5)
Rapid detection of fibrinogen-related antigens in serum. (1973) (5)
Hereditary defects in clotting mechanisms. (1958) (5)
The therapy of hereditary disorders of blood coagulation. (1963) (4)
Hemorrhagic states during pregnancy. (1955) (4)
The Arthus reaction in cats deficient in Hageman factor (factor XII). (1990) (4)
Further studies on the inheritance of Hageman trait. (1962) (4)
The molecular basis of hereditary clotting disorders. (1972) (4)
Disseminated Intravascular Coagulation: An Intermediary Mechanism of Disease (1965) (4)
The role of haemostatic mechanisms. (1981) (4)
The differentiation between extrahepatic and intrahepatic obstruction of the portal circulation; a clinical study of the Banti syndrome. (1950) (4)
Sources of variability in antihemophilic factor (factor VIII) procoagulant titers and precipitating antigen levels among obligate carriers of classic hemophilia. (1981) (4)
Chloroform-induced fibrinolysis. Its dependence on Hageman factor, plasma prekallikrein, and high molecular weight kininogen. (1980) (4)
Inhibition of expression of monocyte interleukin-1 by inhibitors of Hageman factor (factor XII). (1995) (4)
The blood clotting mechanism and its disorders. (1965) (3)
DETECTION OF HAEMOPHILIA CARRIERS (1975) (3)
STUDIES ON A PROTEOLYTIC ENZYME IN HUMAN PLASMA (1948) (3)
Interactions of C1(-)-inhibitors from normal persons and patients with type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa) (1990) (3)
Classic gout in Hageman factor (Factor XII) deficiency. (1982) (3)
Implications of the identification of carriers of chronic disease. (1977) (3)
A – The Physiology of Blood Coagulation (1974) (3)
Proceedings: Fitzgerald factor and surface-mediated reactions. (1975) (3)
A new property of an old remedy: fibrinolysis and aspirin. (1977) (3)
Blood fractions in clinical medicine. (1962) (3)
classics in medicine (1993) (2)
Inheritance of factor XIII. (1970) (2)
Studies on a proteolytic enzyme in human plasma; the rate of lysis of plasma clots in normal and diseased individuals, with particular reference to hepatic diseases. (1949) (2)
Activation of factor XI. (1993) (2)
Interactions among Hageman factor (HG, Factor XII), plasma thromboplastin antecedent (PTA, Factor XI), plasma prekallikrein (PK, Fletcher factor) and high molecular weight kininogen (HMW-K, Fitzgerald factor) in blood coagulation. (1979) (2)
The current status of knowledge about Hageman factor. (1961) (2)
Influence of sex upon the lethal effects of an hepatotoxic alkaloid, monocrotaline. (1949) (2)
Activation of factor XI [letter; comment] (1993) (2)
The activation of PTA (factor XI) and Hageman factor (factor XII). (1965) (2)
The art of betting: which of a bleeder's female relatives is a carrier? (1978) (2)
Tendency to serious sequelae of infection with the human immunodeficiency virus in sibships with hemophilia. (1989) (2)
The laboratory control of anticoagulant therapy. (1962) (2)
Thrombosis and the hypercoagulable state (1984) (2)
Hepatic Damage in Rats Fed Human Foodstuffs.∗ (1955) (2)
Influence of Diet, Sex, and Testosterone Propionate on the Toxicity of Monocrotaline in Rats.∗ (1948) (2)
The hormonal control of the synthesis of Hageman factor (factor XII). Phenomenology and science: friends or foes? (1991) (2)
Diagnosis of the carrier state in hemophilia (1988) (2)
The effect of human plasmin upon cutaneous vascular permeability. (1966) (2)
Hemophilia and the acquired immunodeficiency syndrome. (1985) (2)
Posthepatitic cirrhosis. (1957) (1)
Therapy of hereditary disorders of blood coagulation. (1968) (1)
Modified one-stage hepatectomy in the dog with some notes on the effect of hepatectomy on the coagulability and proteolytic activity of the blood. (1951) (1)
Studies on a proteolytic enzyme in human plasma. VI. Alterations in plasma fibrinogen and proteolytic activity in pneumonia. (1951) (1)
Surface-mediated defenses against injury. (1983) (1)
CHAIRMAN'S INTRODUCTORY REMARKS: DETECTION OF THE CARRIER STATE OF CLASSIC HEMOPHILIA * (1975) (1)
A comparative study of several thromboplastins used to measure the one-stage prothrombin time. (1968) (1)
Clinical Interpretation of Laboratory Tests (1969) (1)
Abolition of the permeability-enhancing properties of Hageman factor by specific antiserum. (1967) (1)
Hemophilia B: Genetics, Hematology and Clinical Aspects (1959) (1)
Mediators of inflammation. (1976) (1)
Anaphylaxis in the Pregnant Rat (1939) (1)
Arterial Thrombosis in Oral Contraceptive Users (1982) (1)
The substructure of antihemophilic factor (AHF, factor VIII): some clearing of the fog. (1977) (1)
Clotting factors. (1970) (1)
PATHOGENESIS OF INFLAMMATION (1965) (1)
Interactions of C1(-)-inhibitors from normal persons and patients with type II hereditary angioneurotic edema with purified activated Hageman factor (factor XIIa). (1990) (1)
The Physiology of Blood Platelets: Recent Biochemical, Morphological and Clinical Research (1965) (1)
The Diagnosis of Bleeding Disorders (1970) (1)
Hereditary disorders of blood coagulation. Deficient synthesis versus defective synthesis. (1971) (1)
Hemophilia and Other Hemorrhagic States (1960) (1)
The activation of human proaccelerin (factor V). (1965) (1)
Conversion Reactions in Their Relationship to the Production of Ecchymoses (2016) (0)
AN ANTICOAGULANT INHIBITING THE ACTIVATION OF A PLASMATHROMBOPLASTICFACTOR (0)
Surface-mediated reactions of blood clotting and related phenomena. (1979) (0)
STUDIES ON T H E ACTIVATION OF A PROESTERASE ASSOCIATED W I T H PARTIALLY P U R I F I E D FIRST COMPONENT OF HUMAN COMPLEMENT* BY IRWIN H. LEPOW, I~.D.$ (2003) (0)
30. Distributive incorporation of mutant A??-chains into fibrinogen molecules. Identification of mendelian proportions of variants in a heterozygous A??#16R ??? H dysfibrinogenemia, fibrinogen amarillo by GPR-phoresis (1998) (0)
"Circulating anticoagulants: a study of 40 cases and a review of the literature. 1961.": an update. (1993) (0)
Radioimmunoassay of human Hageman factor (factor XII). [/sup 125/I tracer technique] (1976) (0)
Carotid sinus syndrome in air crew personnel. (1946) (0)
Humoral mechanisms in inflammation. (1968) (0)
Acute hepatitis in general hospital practice; the role of transfusions and inoculations. (1949) (0)
Oscar D. Ratnoff, MD (2008) (0)
The localized effect on the spinal cord of the intramuscularly injected tetanus toxin (1942) (0)
COMPLEMENT AS A MEDIATOR OF INFLAMMATION ENHANCEMENT OF VASCULAR PEP, MEABILITY BY PURIFIED HUMAN C'I ESrERASE* BY OSCAR (2003) (0)
Activation of Hageman Factor (HF, Factor XII) by Sephadex-Ellagic Acid Mixtures (1977) (0)
Book ReviewSyndromes of Disseminated Intravascular Coagulation: With special reference to shock and hemorrhage. (1966) (0)
The nature of the clotting defect in a case of amniotic fluid embolism (1952) (0)
Hemorrhagic disorders of pregnancy and parturition. (1957) (0)
The ethics of human experimentation. (1988) (0)
The role of c'1q, cations, and ionic strength in the formation of C'1 esterase. (1969) (0)
ATHEROSCLEROSIS. COAGULATION MECHANISMS. (1964) (0)
Editorial: The Laboratory Control of Anticoagulant Therapy (1962) (0)
INTERACTIONS OF ACTIVATED HAGEMAN FACTOR (Factor Xlla, HFa) WITH NORMAL Cl-INHIBITOR (1987) (0)
Recent concepts in the treatment of hepatic disease. (1949) (0)
Newer Concepts Concerning Inflammation: Humoral Mechanisms. (1965) (0)
A Psychiatric Study of Autoerythrocyte Sensitization (2017) (0)
Studier on plasma thromboptastin antecedent hctor XI), PTA deticiency and irrh ion of PTA by plasma: Pharmacologic irvhibritons and specific antberum (1971) (0)
Coagulation and Transfusion in Clinical Medicine (1965) (0)
STUDIES ON THE DETECTION OF THE CARRIER STATE OF CLASSIC HEMOPHILIA (FACTOR VIII DEFICIENCY) (1973) (0)
Some complications of the therapy of hemorrhagic disorders. (1993) (0)
Interactions among Hageman factc molecular weight kininogen, and p) (2016) (0)
The mechanism of rapid fibrinolysis in chronic hepatic disease. (1948) (0)
Autologous antibodies to AHF and phenytoin [letter] (1978) (0)
The effect of chemical modification of basic amino acid residues on the activation and amidolytic activity of Hageman factor (factor XII). (1993) (0)
Abstracts of Papers Presented at the Third International Complement Workshop, Harvard Medical School, Boston, Massachusetts, June 3–5, 1968 (1968) (0)
Autologous antibodies to AHF and phenytoin. (1978) (0)
Surgery in the Hemophiliac (1968) (0)
The Pill: Now and Tomorrow (1970) (0)
Fitzgerald Factor and Surface-Mediated Reactions (1975) (0)
Studies on the Anticoagulant Properties of Chlorazol Fast Pink (Benzo Fast Pink 2BL) 1 (1980) (0)
Hemorrhagic diathesis in pregnancy associated with intrauterine retention of a dead fetus. (1957) (0)
Prothrombin in Enzymology, Thrombosis and Hemophilia (1967) (0)
Toxemia of pregnancy: a medical complication. (1957) (0)
An approach to the diagnosis of disorders of hemostasis. (1968) (0)
The ontogeny of clotting factors. (1988) (0)
An inheritd quahztive abnwmcshy in p4arma fibrinogen: Fibrinoilpan Chknd (1968) (0)
Plasma proteolytic activity in pneumonia. (1950) (0)
Ex vivo studies of human blood protein interactions with cardiopulmonary bypass materials (1991) (0)
Ethical Responsibilities in Clinical Investigation (2015) (0)
Why does the blood not coagulate? (1993) (0)
Deletion of plasma thromboplastin factor D deficiency. (1958) (0)
Treatment of Haemophilia and Other Coagulation Disorders (1967) (0)
A 1973 look at hemophilia and von Willebrand's disease. (1973) (0)

This paper list is powered by the following services:

Other Resources About Oscar Ratnoff

en.wikipedia.org

What Schools Are Affiliated With Oscar Ratnoff?

Oscar Ratnoff is affiliated with the following schools:

Oscar Ratnoff's Academic­Influence.com Rankings

Why Is Oscar Ratnoff Influential?

Oscar Ratnoff's Published Works

Published Works

Other Resources About Oscar Ratnoff

What Schools Are Affiliated With Oscar Ratnoff?

Image Attributions

Oscar Ratnoff's AcademicInfluence.com Rankings